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Abstract
The use of prophylactic antibiotics in patients with severe acute
pancreatitis remains an intensely debated topic. Although animal
studies consistently demonstrated an advantage of antibiotic
prophylaxis, the only two blinded randomized controlled trials could
not confirm these findings. Translation of the experimental models
in human clinical practice is hampered by a number of fundamental
differences between experimental pancreatitis and human disease,
and therefore it is highly unlikely that the pronounced benefit found
in experimental pancreatitis will ever be demonstrated in human
disease. Early and accurate risk stratification to identify the patient
at risk for infection early in the course of the disease seems to be
the greatest challenge. Until we are able to demonstrate an
advantage of antibiotic prophylaxis in a high-risk human population,
the absence of proven benefit and potential side effects of this
strategy should be acknowledged and the use of antibiotics should
be limited to the treatment of documented infection.
Early therapeutic or prophylactic
administration of antibiotics?
In this issue of Critical Care, Fritz and colleagues [1]
describe how, in a rat model of necrotizing pancreatitis,
prophylactic administration of antibiotics reduced mortality at
24 hours after induction of pancreatitis from 57% to 0%.
Furthermore, they compared early antibiotic treatment – anti-
biotics started 24 hours after induction of pancreatitis (that is,
the time frame in which infection of necrosis is expected to
be present) – with prophylactic antibiotic administration and
found that early antibiotic treatment reduced pancreatic
superinfection, but to a lesser extent than prophylactic
administration of antibiotics. Parallel to this observation, they
found that mortality is again significantly lower after
prophylactic antibiotics; animals receiving early antibiotic
treatment had a lower mortality rate compared with controls,
but the difference was not statistically significant (27%
versus 43%).
The originality of this study lies in the ‘early antibiotic
treatment’ arm, in which the investigators aimed to simulate
the clinical situation in which antibiotics are started upon
diagnosis of established infection. Previous animal research
focused mainly on antibiotic prophylaxis versus placebo, with
an advantage for the intervention [2,3]. Fritz and colleagues
demonstrated that, compared with therapeutic administration
of antibiotics, prophylactic antibiotics decreased the rate of
pancreatic superinfection. This has been studied before, and
similar findings were reported by Cinar and colleagues [4].
But in a study by Schwarz and colleagues [5], there was no
difference between prophylactic and early therapeutic
administration of both meropenem and ciprofloxacin in an
animal model.
How to translate these findings in clinical
practice
Although this experimental study suggests an advantage of
prophylactic administration compared with early therapeutic
administration of antibiotics in rats with severe acute pan-
creatitis, it is highly questionable whether the results
observed in this experimental setting can be easily translated
to clinical practice. Several of the arguments advocated by
Fritz and colleagues to explain why randomized controlled
trials on antibiotic prophylaxis in humans did not provide
conclusive results are the same arguments that explain why
the results of animal experiments are of limited use for the
clinician. First of all, in this animal model, a standard
procedure at a predefined moment induces acute
pancreatitis with similar dynamics in all animals, with
extensive necrosis as a result. In human acute pancreatitis,
the situation is completely different: patients with pancreatitis
present at different moments after the start of symptoms, and
thus at different stages of the pancreatitis, with different
causes. Some present early with only mild edema, whereas
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others will present later when necrosis (with variable extent)
or even superinfection has already been established.
Therefore, prophylactic administration of antibiotics before
necrosis is present – if at all desirable – is often not possible
in clinical practice. Second, in this animal model, the exact
moment of bacterial superinfection is well known: within the
first 8 to 24 hours, the necrosis is infected in all animals, but
in human pancreatitis, infection may occur within the first
days but has its highest incidence after 7 to 21 days. In
experimental pancreatitis, it is therefore possible to give
antibiotics effectively, without the risk of developing
resistance due to prolonged exposure to antibiotics or the
risk of selection of microorganisms as observed in human
pancreatitis, which has been documented both in retro-
spective studies [6] as well as the randomized controlled
trials on this subject [7,8]. Third, in the animal model of
pancreatitis, all animals develop pancreatic superinfection,
whereas in human pancreatitis, prediction of who will develop
infection remains one of the most challenging issues in the
management of these patients [9]. The majority of patients will
not develop infected pancreatic necrosis and there are no
reliable tools available for early (that is, within the first days
after the start of symptoms) identification of patients at the
highest risk. Finally, the effects of other (new) interventions
often used in human pancreatitis such as support of organ
dysfunction, the use of enteral nutrition, and so on are not
evaluated in experimental pancreatitis. These factors very likely
will decrease bacterial translocation, which is considered to
be the mechanism that leads to bacterial superinfection, and
therefore may affect the risk for pancreatic infection.
Time for a change
For all of the above reasons, the beneficial effect of prophy-
lactic antibiotics in the ideal standardized setting of experi-
mental necrotizing pancreatitis has not been reproduced
convincingly in any human study, and very likely, this will never
be the case. The reason for this is that acute pancreatitis is a
complex disease with a variable presentation and a highly
unpredictable course, and we are not able to identify – early
in the course of the disease – the patient who is at the
highest risk for infection. This necessitates the inclusion in
clinical studies of a lot of patients who will never develop
infection; in the past, this has led to a lower-than-predicted
incidence of infection, with resulting underpowered studies.
A potential explanation for this is the current array of dogmas
used in severity prediction. We should acknowledge that
there are two major complications in pancreatitis, with a
bimodal distribution of mortality: early organ dysfunction and
late infectious complications. As long as we continue to
define severe disease as either one of these [10] (among
other complications that qualify for the category ‘severe
disease’) and as long as we do not realize that these two
major complications are entirely distinct entities with different
risk profiles, we may not be able to improve the accuracy of
our risk stratification tools.
Role of antibiotics in severe acute pancreatitis
Until we are able to identify the patient truly at risk for
infection and have a treatment modality that has no relevant
side effects and that can be initiated in a timely fashion, the
role of antibiotics in patients with established pancreatitis
remains in the treatment of documented infection. When
suspected, infection should be actively sought, and
computed tomography-guided fine-needle aspiration of the
suspected area should be performed. Timely initiation of
antibiotics is essential in pancreatic infection, just as in any
other (intra-abdominal) infection. Therefore, a low threshold
for an aggressive diagnostic approach to ‘search for and
destroy’ infection is still warranted.
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